Spotlight On Non-Small Cell Lung Cancer
Up to 85 percent of all lung cancer cases are characterized as non-small cell lung cancer, underscoring the importance of keeping up to date on the latest diagnostic and treatment advances. That’s why this Spotlight on Non-Small Cell Lung Cancer brings together leading oncologists and other allied healthcare professionals to discuss key research updates and other novel insights.
Episodes 1-15 of 18
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Project Oncology®Advancing Precision Medicine in NSCLC: Real-World Impact of the PREDICT Initiative
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Project Oncology®AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
Project Oncology®Early Liquid Biopsy in Advanced Lung Cancer: Real-World Data Suggest Targeted Gains
- advertisement
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Project Oncology®AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Project Oncology®Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
NSCLC Care: Evaluating Durvalumab in the First-Line Setting
Project Oncology®NSCLC Care: Evaluating Durvalumab in the First-Line Setting
The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
Project Oncology®The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Project Oncology®Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
Project Oncology®Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
- advertisement
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Project Oncology®Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Recognizing the Role of Capmatinib for METex14 in NSCLC
Project Oncology®Recognizing the Role of Capmatinib for METex14 in NSCLC
Checkpoint Inhibitor Combination Therapy for First-Line Advanced NSCLC
Project Oncology®Checkpoint Inhibitor Combination Therapy for First-Line Advanced NSCLC
